Background
==========

Reversible cognitive impairment associated with the treatment of a prolactin-secreting pituitary adenoma has not been previously described. Herein we report the first case of an invasive giant prolactinoma causing a profound decline in the higher level executive cortical functions as a result of profound short-term memory impairment, which was substantially reversed following the institution of successful decompressive medical therapy.

Case presentation
=================

A 22-year old maths university student was presented with a few weeks\' history of mild headaches. He additionally reported a year\'s long history of gradual and progressive short-term memory deterioration, as evidenced by an unexpected poor performance at his recent examinations. In an attempt to compensate for the rapidly progressing memory problems, the patient started using 'smartphone' messaging and other memory cues. Subsequently, he found that he was receiving messages to remind him of the messages which he could not recall. This unusual and unexplained rapid decline in mentation with headache prompted an urgent MRI brain. It showed a large 48×52×28 mm midline hypervascular partially-cystic and partially solid sellar mass causing a significant brain compression with oedema, and extending into the suprasellar region with cavernous sinus invasion and chiasmal compression ([Fig. 1](#fig1){ref-type="fig"}). On direct questioning, he also complained of erectile dysfunction and decreased shaving frequency, but no galactorrhoea. On examination, he was clinically hypogonadal with significant gynaecomastia, sparse facial, chest and abdominal hair and Tanner stage IV pubic hair. His testes were soft and 20 ml in volume. A Humphrey visual field assessment showed a subtle left superior quadrantanopia. Extraocular eye movements remained intact, and visual acuity was normal.

![T1-weighted coronal MRI pituitary -- view at presentation showing large 48×52×28 mm midline hypervascular cystic sellar mass causing significant brain oedema and extending into the suprasellar region with cavernous sinus invasion and chiasmal compression.](edmcr-2016-150111-g001){#fig1}

Investigation
=============

Urgent anterior pituitary function hormonal assessment revealed marked hyperprolactinaemia of 515 217 mIU/l (N: 0--450) and central hypogonadism (LH 0.9 IU/l (N: 1.8--8.2); FSH 2.1 IU/l (N: 1.4--14.0); testosterone 4.3 nmol/l (N: 6.7--25.7)). Other pituitary axes appeared to be normal ([Table 1](#tbl1){ref-type="table"}). Bone mineral density (BMD) confirmed osteopenia in the lumbar spine (Z-score: −1.9). A diagnosis of a giant invasive cystic prolactinoma with secondary hypogonadotrophic hypogonadism was made.

###### 

Endocrine assessment at baseline, 6 and 12 months following treatment

  **Test**                                  **Presentation**   **6 months**   **12 months**   **Reference range**
  ----------------------------------------- ------------------ -------------- --------------- ---------------------
  Prolactin (mIU/l)                         515 217            6454           448             0--450
  TSH (mU/l)                                0.78               1.56           2.13            0.3--4.7
  Free T~4~ (pmol/l)                        15.2               13.4           13.3            9.5--21.5
  Free T~3~ (pmol/l)                        3.8                4.4            4.2             3.5--6.5
  LH (U/l)                                  0.9                2.5            2.1             1.8--8.2
  FSH (U/l)                                 2.1                4.3            3.3             1.4--14.0
  Testosterone (nmol/l)                     4.3                10.1           14.6            9--25
  GH (μg/l)                                 \<0.1              \<0.1          \<0.1           \<3.1
  IGF1 (nmol/l)                             15                 18             17              5--26
  0900 h Cortisol (nmol/l)                  510                --             --              170--540
  Short Synacthen Test (cortisol; nmol/l)   0 -- 238           0 -- 353       0 -- 351        170--540
                                            30′-- 713          30′-- 568      30′-- 744       
                                            60′-- 797          60′-- 610      60′-- 825       

GH, growth hormone; IGF1, insulin like growth factor 1; LH, lutenizing hormone; FSH, follicle stimulating hormone; TSH, thyroid stimulating hormone; free T~3~, free triiodothyronine; free T~4~, free thyroxine.

The patient completed a standard test of memory, new learning and memory as a baseline. The standard scores were based upon a T distribution with a mean of 50 and [s.d.]{.smallcaps} of 10. The neuropsychological assessment with BIRT Memory and Information Processing Test Battery revealed profound cognitive impairment ([Table 2](#tbl2){ref-type="table"}, column 1), as shown by significantly reduced immediate and delayed figure recall (T score with percentiles were 43, 25 and 35, 7 respectively), design learning (T score: 42, percentile: 20), immediate story recall (T score: 33, percentile: 4), delayed story recall (T score: 32, percentile: 4), and list learning (T score: 39, percentile: 14). The first four scores evaluated functions of learning and retention of complex information, which were very weak. Additionally, some elements of confusion with a degree of confabulation were noted. Despite significant deficiencies in the initial learning of written information as demonstrated in the list of learning and design learning tasks, the patient showed a relatively normal learning curve with a positive improvement on each repetition of material. The overall impression was that the cognitive difficulties appeared to be more complex than a straightforward problem of memory and new learning. Formal diagnosis of profound cognitive impairment of unknown aetiology was made.

###### 

Neuropsychological assessment using BIRT Memory and Information Processing Test Battery at presentation and 6 months following treatment

                     **At presentation**   **After 6 months of treatment**   **Reference range**               
  ------------------ --------------------- --------------------------------- --------------------- ---- ------ ------
  Figure immediate   43                    25                                66                    94   \>52   \>60
  Figure delayed     35                    7                                 61                    87   \>50   \>60
  Design learning    42                    20                                60                    85   \>48   \>60
  Story immediate    33                    4                                 57                    76   \>45   \>60
  Story delayed      32                    4                                 59                    82   \>43   \>60
  List learning      39                    14                                71                    98   \>45   \>60

Treatment
=========

The patient was commenced on cabergoline 250 μg weekly, which he has been taking until present.

Outcome and follow-up
=====================

The patient\'s prolactin levels were rapidly reduced to 119 583 mIU/l after the first two doses, and further to 56 061 mIU/l by week 4. No side effects or complications of treatment were reported. A 3-month follow-up MRI showed a very significant reduction in tumour size ([Fig. 2](#fig2){ref-type="fig"}). Serum prolactin levels fell by 99% within 6 months of treatment, and patient was maintained on low dose cabergoline (250 μg weekly) thereafter until now. The AIP and MEN genes mutation analyses were proved negative. A detailed repeated psychometric assessment performed 6 months following the commencement of dopamine agonist showed complete resolution of cognitive dysfunction ([Table 2](#tbl2){ref-type="table"}, column 2). On three of the four memory tasks, the patient obtained a score at the upper limit for the test, and was deemed to perform within the superior range of ability. The patient has since successfully completed his Masters in Mathematics course and is now working on his PhD in Maths and Computing.

![T1-weighted coronal MRI pituitary -- view following 6 months of cabergoline treatment showing significant tumour shirinkage.](edmcr-2016-150111-g002){#fig2}

Discussion
==========

Reversible cognitive impairment associated with the treatment of a prolactin-secreting pituitary adenoma has not been previously described. Herein, we report the first case of an invasive giant prolactinoma causing a profound decline in the higher level executive cortical functions as a result of profound short-term memory impairment, which was substantially reversed after following the institution of successful decompressive medical therapy.

There were no contributory endocrinopathies, which could be associated with this pattern of impaired cognition. Interestingly, local pressure effects to the surrounding brain area by the patient\'s giant prolactinoma share homology with midbrain arachnoid cysts, which notably have been reported to cause reversible cognitive impairment upon surgical decompression [@bib1]. In a prospective cohort study, Raeder *et al*. [@bib4] showed that although intracystic pressure of arachnoid cysts remained within the limits of normal intracranial pressure, there was a significant correlation between the intracystic pressure and the preoperative level of impaired mental function. Neuroimaging studies proved that arachnoid cysts may affect local perfusion and metabolism, and that those changes can be reversed following cyst decompression, which were also evidenced by clinical and cognitive assessments.

Our patient showed a remarkable recovery from his initially very low scores after just 6 months of cabergoline treatment, allowing him to study for a high-level degree, and associated with a dramatic tumour involution with reduction in pressure on key brain structures, and has remained well until present. Moreover, a 6-month follow-up pituitary MRI confirmed complete resolution of cystic giant prolactinoma.

One final aspect to consider is that a large prolactinoma in a young individual may represent the first manifestation of a MEN-1 syndrome, or be related to a genetic predisposition to develop familial pituitary adenomas. Appropriate genetic testing is, therefore, highly recommended in such cases [@bib5].

In conclusion, giant prolactinomas can be presented with profound cognitive defects because of the local compressive effects. They can also masquerade as other causes of cognitive impairment include arachnoid cysts. Cabergoline was the effective and safe first-line treatment, which, by inducing dramatic tumour shrinkage, resulted in immediate and complete resolution of debilitating cognitive impairment.
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